{"name":"CTI BioPharma","slug":"cti-biopharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"CHOP-R","genericName":"CHOP-R","slug":"chop-r","indication":"Non-Hodgkin lymphoma","status":"phase_2"},{"name":"CT-2106","genericName":"CT-2106","slug":"ct-2106","indication":"Relapsed or refractory acute myeloid leukemia","status":"phase_2"},{"name":"Gemcitabine + Rituximab","genericName":"Gemcitabine + Rituximab","slug":"gemcitabine-rituximab","indication":"B-cell non-Hodgkin lymphoma","status":"phase_3"},{"name":"Pixantrone + Rituximab","genericName":"Pixantrone + Rituximab","slug":"pixantrone-rituximab","indication":"Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","status":"phase_3"},{"name":"pixantrone, cyclophosphamide, vincristine, rituximab, prednisone","genericName":"pixantrone, cyclophosphamide, vincristine, rituximab, prednisone","slug":"pixantrone-cyclophosphamide-vincristine-rituximab-prednisone","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"A: pacritinib","genericName":"A: pacritinib","slug":"a-pacritinib","indication":"Myelofibrosis","status":"phase_1"},{"name":"CPOP-R","genericName":"CPOP-R","slug":"cpop-r","indication":"Other","status":"phase_2"},{"name":"Pixantrone IV infusion","genericName":"Pixantrone IV infusion","slug":"pixantrone-iv-infusion","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"CHOP-R","genericName":"CHOP-R","slug":"chop-r","phase":"phase_2","mechanism":"CHOP-R is a chemotherapy regimen that combines rituximab with a modified version of the CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine, and prednisone.","indications":["Non-Hodgkin lymphoma"],"catalyst":""},{"name":"CT-2106","genericName":"CT-2106","slug":"ct-2106","phase":"phase_2","mechanism":"CT-2106 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Relapsed or refractory acute myeloid leukemia"],"catalyst":""},{"name":"A: pacritinib","genericName":"A: pacritinib","slug":"a-pacritinib","phase":"phase_1","mechanism":"JAK2 inhibitor","indications":["Myelofibrosis"],"catalyst":""},{"name":"CPOP-R","genericName":"CPOP-R","slug":"cpop-r","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Gemcitabine + Rituximab","genericName":"Gemcitabine + Rituximab","slug":"gemcitabine-rituximab","phase":"phase_3","mechanism":"Gemcitabine damages cancer cell DNA while rituximab targets and eliminates B cells expressing CD20, combining chemotherapy with immunotherapy.","indications":["B-cell non-Hodgkin lymphoma","Chronic lymphocytic leukemia"],"catalyst":""},{"name":"Pixantrone + Rituximab","genericName":"Pixantrone + Rituximab","slug":"pixantrone-rituximab","phase":"phase_3","mechanism":"Pixantrone is a topoisomerase II inhibitor that damages cancer cell DNA, combined with rituximab, a CD20-targeting monoclonal antibody that depletes B cells.","indications":["Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)"],"catalyst":""},{"name":"Pixantrone IV infusion","genericName":"Pixantrone IV infusion","slug":"pixantrone-iv-infusion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"pixantrone, cyclophosphamide, vincristine, rituximab, prednisone","genericName":"pixantrone, cyclophosphamide, vincristine, rituximab, prednisone","slug":"pixantrone-cyclophosphamide-vincristine-rituximab-prednisone","phase":"phase_3","mechanism":"Pixantrone is a synthetic anthracenedione that intercalates DNA, thereby inhibiting DNA replication and transcription.","indications":["Relapsed or refractory diffuse large B-cell lymphoma","Multiple myeloma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE43TGlpSXJubENFMzVjUjhST2pFek9hS1M1OHcyZy1oRlJzc2VaUlRJNUt4TXJHWXpQY3htai00ZElGbUZnRmVCeUlfc2h3T2lzZ21jVnRqaXV0WEI3aEwxemRDVXpfeVNzVmdiakhhYw?oc=5","date":"2025-12-15","type":"deal","source":"medwatch.com","summary":"Sweden's Sobi acquires US biotech for up to USD 1.5bn - medwatch.com","headline":"Sweden's Sobi acquires US biotech for up to USD 1.5bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPb0VLVURGRHlrTGtFT0tZaTh2cF9VSWZlaXpkS3piN01RTWZVRXF4a0kzRHZ3NGowcUUyRm0waFljS3NfZkFWamJRcVBNdDdkUy1OVjVEaXY0WV9HWmFaZXVEV050ZHhBMndIbnIzOTk5UWo3ZDdzc3pJeFdWQllObFNjZG1rR0REY1lUWVF2enNsdERSWnJHSUh0VGt3T05md2NMUGVOZ3dpTWR5?oc=5","date":"2025-08-15","type":"trial","source":"Endpoints News","summary":"Stephen Hahn steps down as CEO of Flagship biotech; A new era at AbbVie partner Gubra - Endpoints News","headline":"Stephen Hahn steps down as CEO of Flagship biotech; A new era at AbbVie partner Gubra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQQkpaNXNfb2NvZFF3MWRoMm1XMVQzbVprcnpVQ2QtUUFzaWd6YWRnem5qYmJiRGc1Rnc3aWRxYXRZM3RaR0pYbTVqSEN5bVF1ZG5WQURFZmRRY3NZd1R5ZFFQNk54c3Y4a0FXX3FBV09nVXd4NFEtVTE0LUc3UjNVZkx2LVgtUlJVZmVRSzdrVDhGMl9vcnFNX2N0Zw?oc=5","date":"2025-08-12","type":"pipeline","source":"citybiz","summary":"X4 Pharmaceuticals Announces $60 Million Equity Financing - citybiz","headline":"X4 Pharmaceuticals Announces $60 Million Equity Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1ZMFhhRy1tMmFqcl80V1J1cWdjVUd3ZUhNZ0JqbkpqcHlIMGNZV0dsOXZvY2M4NF8wZXlQdGQweEZPRlZ5WDJITlkwU29KS2c4aE4w?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"CTIC Stock Price, News & Analysis - Stock Titan","headline":"CTIC Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOZGdmcld3eVV4WTlPbi1abmQ0RENUYmhLYWV6U3VqWU0zcnN2WGpJTGJtZmJ6bjdvQ2VyeWV0QXZyeEc2OHhudGpHZW55SGQxRjhtNWdIdk1lY0JvN0M2NU5Lc1ZobFc3dk03azBVWnQ5eEN2M3VrbjR6RDljSF9yZDQ5blJTNi1jNUVuLUdnc3RuQ1FBSVE?oc=5","date":"2023-06-29","type":"deal","source":"PharmTech.com","summary":"Sobi and CTI BioPharma Complete $1.7 Billion Acquisition Deal - PharmTech.com","headline":"Sobi and CTI BioPharma Complete $1.7 Billion Acquisition Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNb0VwWVZEOWE5bnV2amhaOXVLWDk0X00tZll4U0w0d0J0YmNtX1laN1lCa3FwdEVRelN2czN2ZXo4eEFDOEtHN2hhR043dldjLXh6YjVEQmExMDNOUU5zc3oxb2I0SS1kNVN3Tk1HbWgxRXczMmtoSXphVDBrYVFNaVgtVWppdmhqcVdWSmZ1MHJTYk0?oc=5","date":"2023-06-27","type":"deal","source":"Contract Pharma","summary":"Sobi Acquires CTI BioPharma for $1.7 Billion - Contract Pharma","headline":"Sobi Acquires CTI BioPharma for $1.7 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNX0FFdnBDZEV4dzZaSW5VUXhZYkpIeF9jWjJwdGc1QzM2a29DNk5MYnltamNNTEsxQlprUFE4aVJjUWR5SFNkNE54QnB5QkpoNXpIWHh0dkhNWGJPRXdDRDFDUExTWU9XNWMtaENoX0U5THc3Z2Y2bWZ1bmdMMFMydzhSeFpRRFNGLU9MaFZBWQ?oc=5","date":"2023-05-11","type":"pipeline","source":"Biostock","summary":"Sobi makes billion-dollar bid for CTI Biopharma - Biostock","headline":"Sobi makes billion-dollar bid for CTI Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPVnY3a1BHbG96UFZyNldIa290V19ZT0h3MjZRdnVzcWhSU0RUd1JCRGZLcnNPOE5FQVpENy1SeFo2NktTSGpqOUl5RVZrSjFJWm85RkNmR29sRkUyUGhJWHBGUW9kcURpLUtPSjZoRkNUZmJ6eTR3azhUWXlIZWZnZTBKdk9MeVpPTmxfekxJRkJDWkZ3WTRPRl9ka0xoNTRFZVZrTE0zeXhTUTAzbmc?oc=5","date":"2023-05-10","type":"deal","source":"GeekWire","summary":"Swedish drugmaker SOBI to acquire Seattle biotech company CTI BioPharma for $1.7B - GeekWire","headline":"Swedish drugmaker SOBI to acquire Seattle biotech company CTI BioPharma for $1.7B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQR3FGaXFNMlh5amxWUXJPRGdDNGc1R1dnd01lVGVsU05xVFN1OENGV2VyWDdXUkF0bThpNVFqMjd2dkxYcnlwMWlNOUcwNlRvTkdCczNLT3hzSlRBVWxUZUZBUkM4SENFUFMyZnhTOHNiQTVUeG5WcDBrWEE1cW1iQ19mSQ?oc=5","date":"2023-05-10","type":"deal","source":"pharmaphorum","summary":"Sobi sizes up $1.7bn merger with blood cancer biotech CTI - pharmaphorum","headline":"Sobi sizes up $1.7bn merger with blood cancer biotech CTI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQNjdIejVvdGIxZDdnTWt4UEJDY2xzSTNJYmttbXo3MzVoc3J4ZHI3Z1d3WjFTWnpYUHRyeHlRV3RlYkplc2lKcy16N29SYXIzRVhMREhsY042YW1feDlKM2djTGFaYjRTX2VJeERzbGpaSW9xdExpVnc4Qk5Gdm5HRlA4M3BlQjdxWUgzcl9KWGZpMW0xSERZRWU5aWlsaF9xWXFwaThsVDdRcUE4Tzcw?oc=5","date":"2022-03-01","type":"regulatory","source":"Fierce Pharma","summary":"CTI BioPharma clinches long-awaited FDA approval for myelofibrosis blockbuster prospect Vonjo - Fierce Pharma","headline":"CTI BioPharma clinches long-awaited FDA approval for myelofibrosis blockbuster prospect Vonjo","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQMDA3QjlaQkgwVC1NVk9LTVZXRWRkcnRfQmgxenlCVmc3NmZ3V29mcklXdE9IN3RRT0NsZEQ2Q19iTXBiSTJMaXlxdHFkdDZDeDlnVDlKcDhCWS1UclZyX1VRLXhjTTlwUFY5dTJ6a3EyXzdkdzdoTEtHQlVsZGFpQmpSeUswNU1PNlFhdV93Q0p0MXB1MzZWVHpnMU92TmNUUkYxZDVORC0ydVZQTFZQSG9CMWgxMndUc0hGeHREeF9HbDRBVWdwMEV6MTZMa0lNaFlScnAyRktqNnluNjJrNFlhbFY?oc=5","date":"2017-10-26","type":"pipeline","source":"PR Newswire","summary":"CTI BioPharma Prices Underwritten Public Offering of $45 Million of Convertible Preferred Stock - PR Newswire","headline":"CTI BioPharma Prices Underwritten Public Offering of $45 Million of Convertible Preferred Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPUmw5TlZwRmZaVms1ZnhzODZ0T1lpb3FwNll0R3dENDFuUk9IWF96OEF4RDk5bThlTHJVWEE3S2JZZXRhcVB3dVZfTWNfZnRvVFg0WmI1dFhibG5tbmN5UkRfam5oQWZnamR4R21mcktnRXBSRFZFM0hqWjBPN1NLdjU0V1J1TkVmWUhOenBodHVZOGVBTFdNYTNCY1lSVnJ1c1VVMXh1bU1HQXZBSGlGVEt1ODNzZw?oc=5","date":"2016-02-08","type":"regulatory","source":"BioPharma Dive","summary":"Update: After patient deaths, FDA puts CTI BioPharma’s myelofibrosis on full clinical hold - BioPharma Dive","headline":"Update: After patient deaths, FDA puts CTI BioPharma’s myelofibrosis on full clinical hold","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_2":3,"phase_1":2,"phase_3":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}